Dengue virus type 4 envelope protein (DENV4 E protein) (DENV4 E)

The Dengue virus type 4 (DENV4) envelope (E) protein is the primary structural protein on the surface of the DENV4 virion and is the principal target for neutralizing antibodies. It is organized into three domains: Domain I (EDI), Domain II (EDII), and Domain III (EDIII), which collectively mediate viral attachment to host receptors and subsequent membrane fusion. The "genotype II-matched sites" refer to specific amino acid residues within these domains that are characteristic of DENV4 Genotype II, the strain utilized in the development of the Dengvaxia vaccine. Research indicates that vaccine-induced immunity is often highly specific to these matched sites, and variations in other genotypes, such as Genotype I, can lead to reduced neutralization and vaccine breakthrough in seronegative individuals. Consequently, these epitopes are critical for the design of next-generation tetravalent vaccines and therapeutic monoclonal antibodies aimed at providing broad, genotype-independent protection. Understanding the structural and genetic variation of these sites is essential for monitoring viral evolution and ensuring the long-term efficacy of dengue countermeasures.

Other names

DENV4 envelope glycoproteinDENV4 E proteinDengue virus serotype 4 envelope proteinDENV4 genotype II envelope proteinDENV4 type-specific epitopes

Neutralization of viral particles by binding to the envelope protein, thereby blocking viral attachment to host cell receptors and preventing the conformational changes required for membrane fusion and viral entry.